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A B S T R A C T
Previous research has demonstrated the mutation, c.712T>A (p.L238Q) of the gene for α-L- iduronidase
(IDUA) in patients with Hurler-Scheie syndrome is relatively severe when paired with a nonsense or deletion or
splice-site mutation. This mutation was also found to be associated with psychiatric symptoms. This research
presents longitudinal data and protein analysis to further investigate the severity and natural history of these
unique patients.
Methods: Six patients heterozygous for L238Q were compared to six patients with Hurler-Scheie without the
L238Q mutations. Somatic burden of disease, IQ, memory, attention, adaptive functioning and behavioral
measures were given yearly over 2 to 4 years from 2009 to 2014. The impact of L238Q on the IDUA enzyme was
examined using 7 bioinformatics tools and a 3D structural analysis.
Results: Similar to the cross sectional study, the L238Q patients had more severe abnormalities in IQ, attention,
adaptive functioning, and behavioral functioning than the comparison group. There were no major diﬀerences
between the two groups in change over time; IQ for both groups was stable with some behavioral areas showing
improvement. Over time, both groups declined in visual spatial memory and, attention/visual processing. They
also showed increased anxiety. Structural and bioinformatics analysis of the L238Q suggest that this mutation
causes a signiﬁcant reduction in the IDUA enzyme's potential catalytic activity, and this mutation may be more
severe than other mutations contributing to the Hurler-Scheie syndrome phenotype, presumably causing the
psychiatric disease.
Conclusion: L238Q patients demonstrate severe neurocognitive and neurobehavioral deﬁcits but are relatively
stable. Like the comparison group, decreasing visual spatial memory and attention and increasing anxiety
suggest more intervention in life skills and emotional social supports are needed.
1. Introduction
A missense mutation, L238Q, in patients with Hurler-Scheie syn-
drome, has been described as having a spectrum of clinical severity. In
the literature, this IDUA (α-L- iduronidase) mutation has been men-
tioned in diﬀerent levels of severity [1–4]. Previous cross sectional
research of six heterozygous patients has documented the mutation,
c.712T>A (p.L238Q) of the gene for IDUA in Hurler-Scheie syndrome
as relatively severe when paired with a nonsense or other severe mu-
tation, manifested by medical, cognitive complications and also iden-
tiﬁed the mutation L238Q as uniquely associated with a
neuropsychiatric phenotype [5]. Although heterozygosity of mutations
of the GLB gene in Gaucher disease has been associated with Parkin-
son's disease [6], no other speciﬁc mutation of the IDUA gene has been
associated with neuropsychiatric symptoms.
This study extends prior cross-sectional work by investigating how
this same cohort of patients has functioned over time and whether their
life adjustment has been aﬀected. These longitudinal ﬁndings are
compared to a comparison group of non-L238Q patients with Hurler-
Scheie. It was of particular interest to ﬁnd out whether these patients
showed decline in functioning over time. The primary hypothesis tested
in this analysis is that while medical symptoms were likely to worsen
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over time as in other patients with Hurler-Scheie syndrome, their
neurocognitive and neuropsychiatric status would be stable, but remain
within the abnormal range.
In addition, to further understand the impact of L238Q on the IDUA
enzyme, a 3D structural analysis and a combination of bioinformatics
tools were used [7,8] to determine its consequences.
2. Methods
Patients were identiﬁed from MPS I participants with Hurler-Scheie
syndrome in the age range of 14 to 25 years from an NIH-supported
study which is a part of the Lysosomal Disease Network (LDN) (U54-
NS065768). The six patients in the L238Q group were compared to 6
age-matched Hurler-Scheie patients without the L238Q mutation as a
comparison group. All participants are on enzyme replacement therapy
(ERT) and had DNA analysis. Speciﬁcs of their mutations can be found
in Table 1.
2.1. Patients
Of the six patients with L238Q mutation, four were paired with a
nonsense mutation, one with a deletion, and one with a splice site
mutation. For the comparison group, three patients had a missense
paired with nonsense, two patients with missense paired with missense,
and one patient with nonsense paired with splice site mutation.
2.2. Procedures
2.2.1. Somatic disease burden
To measure the somatic disease burden, the Physical Symptom
Score (PSS) [9] was used. It quantiﬁes severity using medical data from
history and by interviewing the research participants or their care-
givers.
2.2.2. Neurocognitive, adaptive, and psychological status
Assessment of neurocognitive functioning, including IQ, memory,
attention, adaptive skills and behavioral function, used following
measures:
● WASI (Wechsler Abbreviated Scale of Intelligence) [10] to obtain
the Full Scale IQ (FSIQ),
● BVMT (Brief Visual Spatial Memory Test) [11] to measure nonverbal
memory,
● TOVA (Test of Variables of Attention) [12] to assess attention,
● VABS-II (Vineland Adaptive Behavior Scales, Second Edition) [13]
to assess adaptive functioning
● BASC-PRS and BASC–SRP (Behavior Assessment System for
Children-Parent Rating Scale and Self-Report of Personality) [14] to
assess psychological status.
2.2.3. DNA analysis
For DNA analysis molecular diagnosis was performed by Sanger
sequencing of all exomes of the IDUA gene at the Gene Therapy and
Diagnostics Lab, University of Minnesota. DNA was isolated from leu-
kocyte pellets, PCR ampliﬁed, and then sequenced with BigDye®
Terminator (Life Technologies). The reactions were sequenated on an
ABI 3130 Avant sequencer (Life Technologies) with subsequent analysis
on Sequencer software (Gene Codes Corporation).
2.2.4. In silico analysis of L238Q
A total of 7 bioinformatics tools were used as described in a previous
study [7,8]. These tools were listed as follows: SIFT (Sorting Intolerant
From Tolerant), PolyPhen (Polymorphism Phenotyping), I-Mutant,
PROVEAN (Protein Variation Eﬀect Analyzer), PANTHER (Protein
Analysis Through Evolutionary Relationships), SNPs&GO (Single Nu-
cleotide Polymorphism Database & Gene Ontology) and PHD-SNP
(Predictor of Human Deleterious Single Nucleotide Polymorphisms).
SIFT and PROVEAN predict the consequences of a single amino acid
substitution by utilizing multiple alignment information. PolyPhen
predicts the impact of an amino acid substitution using straightforward
physical and comparative considerations. I-Mutant can predict protein
stability changes upon single amino acid substitution. PANTHER makes
prediction with hidden Markov model (HMM) based statistical mod-
eling methods and multiple sequence alignments (MAS). Both PHD-SNP
and SNPs&GO are support vector machine (SVM) classiﬁers using su-
pervised training to predict functional impacts of amino acid substitu-
tions.
The impact of L238Q was predicted by a total of 7 bioinformatics
tools using diﬀerent methodologies. The associated index that indicates
the conﬁdence of prediction was given and explained as followed:
SIFT: tolerated, if the index is< 0.05; and damaging, if the index is
≥0.05.
PolyPhen: benign, if the index is< 0.15; probably damaging, if the
index is> 0.85; and possibly damaging;> 0.15.
I-Mutant: neutral, if the index is−0.5 to<0.5; and large decrease,
if the index is<−0.5.
PROVEAN: neutral, if the index is>−2.5; and deleterious, if the
index is<−2.5.
PANTHER, SNPs&GO and PHD-SNP are using a probability score (0
to 1).
2.2.5. 3D Structural Analysis
A 3D structural analysis was performed to reveal the impact of the
Table 1
Mutation and medical data of L238Q and comparison group.
Mutation Mutation type Hydrocephalus Shunt placement Cord compression Psychiatric problem Sleep problem
L238Q group
1 L238Q/63delC Missense/Deletion Absent Absent Present Present Present
2 L238Q/W402X Missense/Nonsense Present Present Present Present Present
3 L238Q/W402X Missense/Nonsense present Absent Present Present Present
4 L238Q/W402X Missense/Nonsense Present Present Absent Present Present
5 L238Q/W402X Missense/Nonsense Present Present Present Present Present
6 L238Q/Int3-2a> g Missense/Splice Site Absent Absent Absent Present Present
Compari-son group
7 G256R/ W402X Missense/Nonsense Absent Absent Absent Absent Absent
8 G265R/A327P Missense/Missense Absent Absent Absent Absent Absent
9 Q380R/Q70X Missense/Nonsense Absent Absent Absent Absent Absent
10 P533R/P533R Missense/Missense Absent Absent Absent Absenta Absent
11 R89W/W402X Missense/Nonsense Present Absent Present Absent Absent
12 W402X/Int11-7c> t Nonsense/Splice Site Absent Absent Present Absent Absent
a This patient has a diagnosis of depression after his 3rd visit and was on anti-depressant thereafter.
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L238Q on the IDUA enzyme.
2.3. Ethical considerations
All patients and/or their legal guardians provided written informed
consent to participate in the study. This study was approved by the
University of Minnesota Institutional Review Board: Human Subjects
Committee. The protocol was approved by each site's institutional re-
view board or independent research ethics committee. The authors
conﬁrm independence from any of the funder of this research; the
content of the article has not been inﬂuenced by any of the funder.
2.4. Statistical analysis
Descriptive statistics were tabulated separately for L238Q and
comparison Hurler-Scheie groups. These included the mean and stan-
dard deviation for continuous variables and frequency with percentages
for categorical variables. Linear regression based on generalized esti-
mating equations was used to estimate the ﬁrst-order trend in neuro-
cognition and behavioral scores over time separately for each group and
compared to each other. Conﬁdence intervals and P-values were based
on robust variance estimation to account for the correlated nature of
longitudinal measurements. The Holm procedure was used for state-
ment on multiple comparisons [15]. All analyses were conducted using
R v3.2.4 [16].
3. Results
1. Mutation and medical data are presented in Table 1.
Table 2 summarizes the demographic, PSS, neurocognitive and be-
havioral/psychological data. Higher physical symptom scores reﬂect
greater disease burden. IQ, BVMT, TOVA, VABS scores are reported as
standard scores with a mean of 100 and standard deviation of 15;
higher scores reﬂect better abilities. BASC scores are reported as T
scores with a mean of 50 and standard deviation of 10; higher scores
reﬂect increased psychological problems.
There were three males in the L238Q group and ﬁve males in the
comparison group. Age of ﬁrst assessment was slightly earlier in L238Q
group. No diﬀerence was found in age at which ERT treatment was
started between the two groups, but the comparison group had a longer
history of ERT treatment. The PSS average was similar between the two
groups, although more surgeries occurred in the comparison group as
the two oldest patients were included in that group, reﬂecting the in-
crease in surgeries with age.
2. Neuropsychological and behavioral results indicated continued
lower functioning in the L238Q group relative to the comparison
group as seen in Table 2. However, comparing slopes across time
between the two groups suggested relative stability in functioning
with the exception of a few variables described below. Table 3 de-
scribes the slopes for the two groups and the comparisons between
them.
3. MPS-speciﬁc physical symptom score (PSS) increased with age in
both groups indicating progressive somatic burden of diseases (See
Fig. 2). The diﬀerence of the marginal slopes between the two
groups is not statistically signiﬁcant (See Table 3).
4. FSIQ scores increased 0.45 point in the L238Q group and 1.68 point
in the comparison group, on average, per year. The diﬀerence of the
marginal slopes between the two groups is not statistically sig-
niﬁcant (0.295) (See Table 3); although the mean FSIQ was below
the average range in the L238Q group and in the average range in
the comparison group (See Table 2, Fig. 3).
5. The visual spatial memory score was almost 2 SD below average in
the L238Q group and just below average for the comparison group
(See Table 2, Fig. 4). The diﬀerence of the marginal slopes across
individuals per year between the two groups was statistically sig-
niﬁcant (0.05) (See Table 3).
6. Average attention scores were within the lower average range in
TOVA-d prime (See Table 2, Fig. 5) and almost 1 SD below the
average range for TOVA- variability in L238Q group (See Table 2,
Fig. 6). For the comparison group all these scores in TOVA were
within the average range (See Table 2). The diﬀerences of the
marginal slopes between the two groups were not statistically sig-
niﬁcant (See Table 3).
7. Adaptive functioning scores did not change over time but the range
was almost 1.5 SD below average in the L238Q group and average in
the comparison group (See Table 2, Fig. 7). While both groups de-
clined in adaptive skills over time, the marginal slopes between the
two groups was not statistically signiﬁcant (See Table 3).
8. On the behavioral measures, average scores on PR-anxiety increased
in severity (See Fig. 8) but scores on PR-depression (See Fig. 9), PR-
withdrawal, and PR-atypicality (e.g. stares blankly, says things that
do not make sense, seems unware of those around him/her) were
improved by parent-report (PR) over time. The diﬀerences of the
marginal slopes of PR-anxiety, PR-depression, PR-withdrawal be-
tween the two groups were not statistically signiﬁcant (See Table 3).
The diﬀerence of the marginal slopes between the two groups for
PR-atypicality was statistically signiﬁcant (p < .001) with both
groups improving. The statistical signiﬁcance of each of the parent
and self-report on atypicality BASC domain is retained after ac-
counting for multiple comparisons.
9. Average scores on SR-depression worsened in the L238Q group and
were still below average (See Fig. 11). Scores on SR-anxiety
Table 2
Patient descriptive: values are mean (SD) or N (%) where indicated. PSS and
below are calculated from within individual average across visits.
Covariates L238Q group Comparison group
N=6 N=6
Male 3 (50%) 5 (83.3%)
2 Visits 0 (0.0%) 1 (16.7%)
3 Visits 3 (50.0%) 2 (33.3%)
4 Visits 3 (50.0%) 3 (50.0%)
Age (years) 17.6 (1.54) 19.2 (4.72)
Age at 1st treatment (years) 10.6 10.6
Number of years on treatment 8.3 (1.3) 9.9 (1.2)
Physical Symptom Score (PSS) 11.2 (0.9) 10.5 (1.8)
Number of surgeries 6.0 (1.4) 9.4 (3.2)
Neuropsychological measures: standard scores 100 ± 15
WASI IQ 75.0 (5.06) 99.4 (13.2)
BVMT 63.2 (17.4) 82.5 (15.7)
TOVA-d prime 80.1 (11.8) 98.4 (16.2)
TOVA-reaction time 92.3 (20.6) 104 (16.0)
TOVA-variability 77.2 (18.5) 94.6 (24.8)
VABS-composite 69.9 (3.12) 88.7 (14.0)
VABS-daily living skills 68.2 (4.27) 84.9 (13.7)
BASC: T scores 50 ± 10
Parent report (PR); Anxiety 53.1 (8.3) 48.5 (7.5)2a
Parent report (PR); depression 57.9 (12.4) 45.4 (6.6) 2
Parent report (PR); withdrawal 63.3 (12.3) 50.2 (11.5) 2
Parent report; atypicality 57.0 (12.1) 42.1 (3.0) 2
Self-report (SR); anxiety 53.5 (10.3) 49.6 (9.8)
Self-report (SR); depression 58.5 (14.3) 45.8 (7.0)
Self; atypicality 68.2 (4.27) 84.9 (13.7) 1
a Superscripts indicate number of cases with missing data.
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worsened for both groups, but especially the L238Q group (See
Fig. 10). SR-atypicality scores were improved by self-report (SR)
over time for both groups. The diﬀerence of the marginal slopes
between the two groups for SR-atypicality is statistically signiﬁcant
(p < .001) with more improvement in the comparison group (See
Table 3).
10. All tools predicted L238Q to be damaging or pathogenic with the
associated index shown in Table 4.
L238Q leads to conversion of leucine into glutamine at position 238.
As shown in Fig. 1, the wildtype residue leucine is smaller and buried in
the core of the protein; thereby the mutant residue glutamine probably
will not ﬁt. Further, this mutation will cause loss of hydrophobic in-
teractions in the core of the protein. In addition, L238 is located in the
TIM barrel domain that is important for catalytic activity and in contact
with residues in another domain. The interaction between these do-
mains could be disturbed by the mutation, which may aﬀect the func-
tion of IDUA enzyme.
11. The 3D structure of native IDUA protein was retrieved from the
RCSB database (PDB ID: 3w81). The mutant model of L238Q was
built through the online server of SWISS-MODEL (https://
swissmodel.expasy.org/interactive) using the native structure as
the template. The Swiss-PDB Viewer, a free molecular graphics
program was used for viewing the modeled structures. In addition,
Project Have Our Protein Explained (HOPE; http://www.cmbi.ru.
nl/hope/home) was used to analyze the structural impact of L238Q
on the whole IDUA protein (Fig. 11).
4. Discussion
No biochemical or clinical guidelines have been established that
reliably distinguish among the three clinical descriptions; severe Hurler
syndrome, attenuated Scheie syndrome, or the intermediate Hurler-
Scheie syndrome in mucopolysaccharidosis type I (MPS I). Hurler-
Scheie and Scheie syndrome, are a spectrum of disorders without
clearly deﬁned diagnostic criterion [17,18]. Genotype-phenotype as-
sociations for missense mutations are not clearly deﬁned. Missense
mutations have widely variable presentations in individuals ranging
from mild to severe [19]. Missense mutations can prevent any func-
tional enzyme activity or can allow for some functional enzyme to be
produced [19,20].
The missense mutation, L238Q, is associated with signiﬁcant cog-
nitive impairment and psychological impacts. L238Q mutation, when
paired with nonsense, deletion or splice site mutation is more severe
than most other patients with Hurler-Scheie syndrome [5]. Therefore,
we examined the structure of the mutation as well as used bioinfor-
matics tools to examine the severity of the mutation. The structural
analysis suggests the L238Q mutation may have disturbing inﬂuences
on the function of the IDUA enzyme. Further analysis using bioinfor-
matics tools suggests that all tools used (SIFT, PolyPhen, I-Mutant,
PROVEAN, PANTHER, SNPs&GO and PHD-SNP) predicted the dama-
ging eﬀect of L238Q to the functional enzyme [7,8].
Table 3
Marginal slope across individuals per year in age.
Score N L238Q Group Comparison Group Slope L238Q vs P-value
Slope per year (95%CI) Slope per year (95% CI) Comparison (95% CI)
PSS 12 0.16 (−0.09, 0.40) 0.25 (0.04, 0.46) −0.09 (−0.42, 0.23) 0.566
IQ 12 0.45 (−1.15, 2.05) 1.68 (0.03, 3.33) −1.23 (−3.53, 1.07) 0.295
BVMT 12 −5.32 (−9.03, −1.62) −1.08 (−3.15, 0.98) −4.24 (−8.48, 0.00) 0.050
TOVA: d prime 12 −1.47 (−4.45, 1.51) 0.48 (−0.67, 1.62) −1.95 (−5.14, 1.25) 0.232
TOVA: reaction time 12 −3.99 (−9.70, 1.72) −2.43 (−4.12, −0.74) −1.56 (−7.52, 4.40) 0.608
TOVA: variability 12 −4.13 (−7.45, −0.82) −2.76 (−4.77, −0.74) −1.38 (−5.25, 2.50) 0.487
Vineland: composite 12 0.00 (−1.28, 1.28) −0.34 (−2.92, 2.24) 0.34 (−2.54, 3.22) 0.818
Vineland: DLS 12 −0.45 (−2.13, 1.22) −1.04 (−3.53, 1.46) 0.58 (−2.42, 3.59) 0.704
BASC PR: anxiety 10 1.59 (−0.73, 3.91) 0.22 (−1.92, 2.36) 1.37 (−1.79, 4.52) 0.395
BASC PR: depression 10 −1.77 (−6.16, 2.62) −0.69 (−2.33, 0.95) −1.08 (−5.77, 3.61) 0.652
BASC PR: atypicality 10 −4.69 (−7.24, −2.13) −0.29 (−0.80, 0.23) −4.40 (−7.01, −1.80) <0.001
BASC PR: withdrawal 10 −3.63 (−5.18, −2.08) −1.83 (−4.15, 0.48) −1.79 (−4.58, 0.99) 0.207
BASC SR: anxiety 12 1.11 (−2.37, 4.58) 1.42 (0.32, 2.53) −0.32 (−3.97, 3.33) 0.864
BASC SR: depression 12 −1.74 (−7.82, 4.33) 1.11 (0.35, 1.87) −2.86 (−8.98, 3.27) 0.361
BASC SR: atypicality 10 −5.03 (−6.19, −3.87) −0.92 (−3.05, 1.21) −4.10 (−6.53, −1.68) <0.001
Table 4
Prediction of L238Q by multiple bioinformatics tools.
SIFT PolyPhen I-MUTANT PROVEN PANTHAR SNPs&GO PHD-SNP
Prediction Damaging Probably damaging Large decrease Deleterious Disease Disease Disease
Associated Index 0.002 1 −2.05 −5.33 0.553 0.513 0.777
Fig. 1. Close-up view of superimposed structure of native and mutant residues
of L238Q. The main protein core is shown in white color while the wild type
and mutated residues are shown in red and green color, respectively. (For in-
terpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
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This study is the ﬁrst to track the longitudinal neurocognitive and
neurobehavioral functioning of patients with L238Q mutations paired
with a severe mutation. Given previous cross sectional ﬁndings that
these patients have more impairment in cognition, memory, attention,
and adaptive behavior than patients with Hurler-Scheie with other
mutation types, it was crucial to clarify whether the pairing of L238Q
mutations with a severe mutation could be associated with any wor-
sening across time. We followed these patients over a 2 to 4 year period
of time and the same diﬀerences were found in level of impairment
between the two groups as the cross sectional study. IQ scores stayed
the same in the L238Q group but slightly improved in the comparison
group although not statistically signiﬁcant. Stability in IQ is consistent
with previous cross-sectional ﬁndings in patients with Hurler-Scheie
[21].
There were a few cognitive areas that did suggest some worsening,
even in the face of stable IQ scores. Visual spatial memory worsened in
both groups, with a marked statistically signiﬁcant decrease in the
L238Q group. Similarly, measures of processing speed (reaction time
and variability) slightly worsened in both groups, but did not diﬀer
between groups. The d′ prime score (a measure of accuracy of
response), while not statistically signiﬁcant, showed a slightly wor-
sening pattern in the L238Q patients with a slightly improving pattern
in the comparison group. Poor and worsening performance on these
tasks may be associated with white matter abnormalities in these pa-
tients [22,23]. Neurocognitive outcomes are functional marker that can
be used to identify the disease severity in Hurler syndrome [24,25] and
are now being used as endpoints for clinical trials of new treatments
[26].
Adaptive functioning, while showing impairment in the L238Q
group and normal range function in the comparison group appeared to
show a slight decline over time, especially in the comparison group. The
two groups were not diﬀerent in their slopes. However, the ﬁnding of
increasing somatic involvement as measured by the PSS over time is
very likely contributing to decreasing ability to carry out activities of
daily living resulting in decreased scores on the measure of adaptive
functioning. Also physical disability can lead to psychological impacts
Fig. 2. PSS of L238Q vs comparison.
Fig. 3. IQ of L238Q vs comparison.
Fig. 4. BVMT of L238Q vs Comparison.
Fig. 5. TOVA d prime of L238Q vs Comparison.
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and eventually decrease motivation to perform in school or daily living
skills.
From the medical history, three patients had shunted hydrocephalus
in the L238Q group compared with one patient with hydrocephalus
without shunt placement in the comparison group. Four patients had
cord compressions in the L238Q group compared with two in the
comparison group. All of the L238Q patients had at least one episode of
depression, psychosis, or autism and they all were on psychotropic
medications and all had sleep problems. None of the comparison sub-
jects had such episodes except one, who had a diagnosis of depression
after his 3rd visit and started anti-depressant medication. On ratings of
behavior and psychological status, parents reported improvement in the
L238Q patients in depression, level of withdrawal and atypical beha-
viors, but an increase in anxiety. Atypical behaviors improved sig-
niﬁcantly in the L238Q group. Parents of the comparison group
reported stability in these behaviors, all within the normal range, with a
slight improvement in the withdrawal score.
Self-report is somewhat diﬀerent with increasing anxiety and de-
creasing atypical behaviors in both groups, perhaps reﬂecting the im-
proving awareness of the patients over time. The presence of atypical
behaviors was statistically signiﬁcantly improved in the L238Q group
compared to the comparison group (See Table 3). A diﬀerence is seen in
the self-report of depression with the L238Q group reporting slight
improvement and the comparison group slight worsening (not statisti-
cally diﬀerent). It should be noted that the scores on these measures of
behavior are very variable, contributing to the lack of statistical sig-
niﬁcance. However, that variability may reﬂect the actual ﬂuctuation in
behavioral or psychological status in these children who may suﬀer
rejection and other stresses, in addition to direct disease eﬀects. It is
possible that the increased incidence of spinal cord compression and
Fig. 6. TOVA-Variability of L238Q vs Comparison.
Fig. 7. Vineland Composite of L238Q vs Comparison.
Fig. 8. Parent Anxiety of L238Q vs Comparison.
Fig. 9. Parent Depression of L238Q vs Comparison.
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hydrocephalus may have had an impact on the behavioral status of
these patients. Previous research has found hydrocephalus also
common in MPS II and MPS VI but they do not present with signiﬁcant
neurocognitive or psychiatric manifestations [27].
With regard to limitations of this study, two of the patients in the
comparison group did not have equivalent mutations (had two missense
mutations). However, their data does not indicate that these two pa-
tients had diﬀerent PSS, cognitive, or behavioral scores than those with
other types of mutations. Finding comparable mutations is challenging
in such a rare disease. Another limitation is the lack of knowledge about
the polymorphism variants in IDUA gene which may have played a role
in their genotype-phenotype correlation. It is mentionable that four
patients from the L238Q group and two patients from the control group
were eligible for and participated in a Food and Drug Administration
Investigational New Drug (IND) approved clinical trial of intrathecal
(IT) enzyme replacement therapy.
5. Conclusions
It can be concluded that Hurler-Scheie patients heterozygous for the
L238Q mutation together with a severe mutation appear to have a
greater signiﬁcant central nervous system impact compared to the
comparison group. The L238Q mutation is associated with a signiﬁcant
impact on FSIQ, memory, attention, adaptive functioning, and beha-
vioral/psychological measurements with below average functioning. IQ
appears stable but visual spatial memory and attention/processing
abilities appear to decline relative to normal values in both the L238Q
and in the comparison group. Somatic symptoms and adaptive func-
tioning worsen in both groups. Depression, withdrawal, and atypicality
improve, but anxiety is worsen as these patients grow older. Because
the L238Q patients seem to be more severely impacted neurocogni-
tively and vulnerable to neuropsychiatric abnormalities than other
Hurler-Scheie syndrome patients, they will need even more attention to
life skills, educational interventions, emotional/social supports, and
eﬀorts at improving the quality of life. Methods of early treatment need
to be considered that will impact the brain in MPS I patients hetero-
zygous for the L238Q mutation.
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